News & Updates
Filter by Specialty:

Real-world data support FTD/TPI plus bevacizumab for mCRC
A combination regimen comprising trifluridine/tipiracil (FTD/TPI) and bevacizumab demonstrates favourable efficacy and safety in individuals with metastatic colorectal cancer (mCRC) in the real-world BeTAS study presented at ASCO GI 2025.
Real-world data support FTD/TPI plus bevacizumab for mCRC
03 Mar 2025
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025
ARANOTE: Darolutamide plus ADT delays progression in mHSPC
The use of darolutamide (DARO) in addition to androgen deprivation therapy (ADT) is effective at improving radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared with placebo plus ADT, irrespective of disease volume, according to the subanalysis of the phase III ARANOTE trial.
ARANOTE: Darolutamide plus ADT delays progression in mHSPC
28 Feb 2025
Low-dose aspirin halves recurrence risk in select CRC patients
In colorectal cancer (CRC) patients harbouring mutations in the PI3K pathway, adjuvant treatment with aspirin 160 mg daily reduced the recurrence rate by over 50 percent, according to the 3-year results from the ALASCCA trial.